Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to ...

Elevate your MedEd strategy with our 2025 toolkit! From AI-driven patient avatars to interactive augmented reality scenarios, ...

Gower is recognised as one of the world’s leading publishers of specialist business and management books and resources. Our publishing programme covers many of the main business processes and ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer ...

Please find below the latest White Papers provided by agencies and companies within the healthcare and pharmaceutical industry. These are provided by external comoanies and are not approved of, ...

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our planet. But are those connections working for or against your… ...

Novo Nordisk has announced an investment of 8.5 billion Danish kroner, or approximately $1.2bn, to establish a new rare disease production facility in Odense, Denmark. Construction on the new site, ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate in a deal worth over $2bn. The agreement gives Merck a ...

Gilead Sciences’ seladelpar has been recommended by the European Medicines Agency’s human medicines committee to treat the rare liver disease primary biliary cholangitis (PBC). The Committee for ...

Established in 2006 by a group of highly experienced outsourcing business specialists, Apodi provides comprehensive outsourcing solutions to pharmaceutical and healthcare businesses and organisations.

Merck & Co – known as MSD outside of the US and Canada – has shared positive results from a late-stage trial of a Keytruda (pembrolizumab)/Lynparza (olaparib) regimen as a first-line treatment for ...